Showing 1 - 20 results of 37,424 for search '(((( ai large decrease ) OR ( _ ((teer decrease) OR (_ decrease)) ))) OR ( a small decrease ))', query time: 0.65s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…<p>Explanation of why accuracy decreases for methods that do not use temporal information (<i>LF</i>, <i>NLF</i>) as <i>k</i> increases. …”
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Changes in TEER with increasing culture time on days 1–22. (<b>B)</b> BA alleviated the LPS-induced decrease in TEER in Caco2 cells after treatment for 24 h. …”
  11. 11

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
  12. 12
  13. 13

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  14. 14

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

    Published 2025
    “…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”